Idera Pharmaceuticals, Inc.
505 Eagleview Blvd., Suite 212
Exton, Pennsylvania 19341
June 10, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|
Attention: |
Ada Sarmento |
|
|
|
|
Re: |
Idera Pharmaceuticals, Inc. |
|
|
Registration Statement on Form S-3 |
|
|
Filed June 2, 2020 |
|
|
File No. 333-238868 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Idera Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended, so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on June 11, 2020, or as soon as practicable thereafter.
IDERA PHARMACEUTICALS, INC.
|
By: |
/s/ JOHN J. KIRBY |
| |
|
|
Name: |
John J. Kirby |
|
|
|
Title: |
Chief Financial Officer |
|